Back to News
Market Impact: 0.3
IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%
Source: zacks.com
Company FundamentalsCorporate EarningsConsumer Demand & Retail
IRIX reported a Q2 loss per share that widened year over year while revenue declined, as Middle East disruptions and weaker sell-through in China weighed on retina sales. Cyclo G6 continued to grow, but the product-family gains were not enough to offset declines in the core retina segment.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
IRIX-0.55
More News
- Delta Air Lines cuts 2026 forecast on fuel surge, but CEO says demand is still strong
- Is AI the new China Shock?
- Why is T-Mobile stock tumbling today?
- The AI race may be decided by financing—not just better chips
- Why is Verizon stock sliding today?
- AI-related companies to drive most third-quarter US earnings gains